Combined cardio-renal failure: A key factor in heart failure progression and therapy;Insuficiencia combinada cardiorrenal: Una clave evolutiva y terapéutica en el fallo cardíaco

Revista Espanola de Cardiologia

Volumn 59, Issue 2, 2006, Pages 87-90

  Caramelo, Carlos ^a   Gil, Paloma ^b  

^a Imagen Cardiovascular Fundación Jiménez Díaz Capio Madrid España   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR ALPHA; CAPTOPRIL; CONIVAPTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; FOSINOPRIL; FUROSEMIDE; NESIRITIDE; TOLVAPTAN; TORASEMIDE;

ADJUVANT THERAPY; ANEMIA; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE COURSE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; EDITORIAL; GLOMERULUS FILTRATION; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MORTALITY; PREDICTION; PRESCRIPTION; PROGNOSIS;

EID: 33645555537     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13084633     Document Type: Editorial

References (18)

1. Gil P, Justo S, Caramelo C. Cardio-renal failure: an emerging clinical entity. Nephrol Dial Transplant. 2005;20:1780-3.
2. De Santo NG, Cirillo M, Perna A, Pollastro RM, Frangiosa A, Di Stazio E, et al. The kidney in heart failure. Semin Nephrol. 2005;25:404-7.
3. Grigorian-Shamagian L, Varela-Román A, Pedreira-Pérez M, Gómez-Otero I, Virgós-Lamela A, González-Juanatey JR. La insuficiencia renal es un predictor independiente de la mortalidad en pacientes hospitalizados por insuficiencia cardíaca y se asocia con un peor perfil de riesgo cardiovascular. Rev Esp Cardiol. 2006;59:99-108.
4. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme, ramipril, on cardiovascular events in high risk patients. The Head Outcomes Evaluation Study Investigators. N Engl J Med. 2000;342:145-53.
5. Hansson L, Zanchetti A, Carruther SG, Dahlöf B, Elmfeldt D, Juluis S, et al; for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1999;351:1755-63.
6. Segura J, Campo C, Gil P, Roldan C, Vigil L, Rodicio JL, et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol. 2004;15:1616-22.
7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC7 Report. JAMA. 2003;289:2560-72.
8. Lupón J, Urrutia A, González B, Herreros J, Altimir S, Coll R, et al. Significado pronóstico de los valores de hemoglobins en pacientes con insuficiencia cardíaca. Rev Esp Cardiol. 2005;58:48-52.
9. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775-80.
10. De Silva R, Nikitin NP, Witte KK, Rigby AS, Goode K, Bhandari S, et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J. 2005; Dec 19; [Epub ahead of print].
11. Kazmi WH, Kausz AT, Khan S, Abichandani R, Ruthazer R, Obrador GT, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis. 2001;38:803-12.
12. O'Meara E, Chong KS, Gardner RS, Jardine AG, Neilly JB, McDonagh TA. The Modification of Diet in Renal Disease (MDRD) equations provide valid estimations of glomerular filtration rates in patients with advanced heart failure. Eur J Heart Fail [serie en Internet]. 2005 Dic [publicado 19 Dic 2005]. 2006;8:63-7.
13. Ezekowitz J, McAlister FA, Humphries KH, Ezekowitz J, Norris CM, Tonelli M, et al. The association among renal insufficiency, pharmacotherapy and outcomes in 6427 patients with heart failure and coronary artery disease. J Am Coll Cardiol. 2004;44:1587-91.
14. Golestaneh L, Talreja A, Le Jemtel TH. Vasopressin antagonists in heart failure. Curr Heart Fail Rep. 2004;1:190-6.
15. Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, et al. Vasopressin-2 receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273-F8.
16. Silver MA. The natriuretic peptide system: kidney and cardiovascular effects. Curr Opin Nephrol Hypertens. 2006;15:14-21.
17. Cheng JW, Merl MY, Nguyen HM. Effect of nesiritide on renal function: a retrospective review. Curr Med Res Opin. 2005; 21:1857-63.
18. Chatterjee PK. Pleiotropic renal actions of erythropoietin. Lancet 2005;365:1890-2.